Home Newsfeeds B of A Securities Downgrades Boise Cascade to Underperform

B of A Securities Downgrades Boise Cascade to Underperform

B of A Securities analyst George Staphos downgrades Boise Cascade (NYSE:BCC) from Neutral to Underperform.

byBenzinga Newsdesk

October 13, 2022

1 minute read

B of A Securities analyst George Staphos downgrades Boise Cascade (NYSE:BCC) from Neutral to Underperform.

A Look Into DXC Technology’s Debt

By Benzinga Insights

January 4, 10:44 AM

Shares of DXC Technology Inc. (NYSE:DXC) rose by 3.32% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.

DXC

Volcon, Inc. Announces $9M In Securities Offerings And Pricing Of Previously Announced Public Offering

By Benzinga Newsdesk

May 22, 8:51 AM

Volcon Inc. (NASDAQ:VLCN), ("Volcon" or the "Company"), the first all-electric, off-road powersports company, today announced the pricing of an underwritten public offering (the "Offering") with gross proceeds to the

VLCN

Telsey Advisory Group Maintains Market Perform on Under Armour, Raises Price Target to $11

By Benzinga Newsdesk

December 22, 6:10 AM

Telsey Advisory Group analyst Joseph Feldman maintains Under Armour (NYSE:UAA) with a Market Perform and raises the price target from $9 to $11.

Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters

By Happy Mohamed

March 3, 9:31 AM

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli

DRTS

B of A Securities Downgrades Boise Cascade to Underperform

Related Posts

A Look Into DXC Technology’s Debt

Volcon, Inc. Announces $9M In Securities Offerings And Pricing Of Previously Announced Public Offering

Telsey Advisory Group Maintains Market Perform on Under Armour, Raises Price Target to $11

Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters